# Ruilin Biomedical Nanjing Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruilin-biomedical-nanjing-co

- Industry: Healthcare Specialists
- Headquarters: Nanjing, China
- Total disclosed funding: $36M
- Latest round: Series A (Jan 16, 2023)
- Investors on record: 5

## About

Established in 2021 and based in Nanjing, China, Ruilin Biomedical Nanjing Co., Ltd. operates as a regenerative medicine technology developer that provides tissue and organ repair and regeneration products. Xing Zhao is the founder of the company, who served as lecturer of Orthopaedic at Harvard University, and served as researcher in Vericel Corporation that is a regenerative medicine public enterprise. The company established plant with 2,000 square meters in Nanjing.  

The company provides tissue and organ repair and regeneration products. It adopts organic combination technology of multi-source cells and 3D printed bio-scaffold materials. Its products focus on orthopaedic sports medicine and plastic surgery fields, including articular hyaline cartilage, osteochondral, meniscal repair and external ear reconstruction.

## Funding rounds

- Series A, Jan 16, 2023, $36M — Jiuyo Capital, Watson Capital, Yingdi Capital, Shanghai Biomedical Fund
- Angel, Feb 22, 2022 — Jiuyo Capital, Yingdi Capital, DAO Capital

## Investors

- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Angel, Series A
- Yingdi Capital — Angel, Series A
- DAO Capital (https://capitalatlas.ai/funds/dao-capital) — Angel
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Shanghai Biomedical Fund — Series A